Non tuberculous anti-TNF associated opportunistic infections;Infections opportunistes non tuberculeuses au cours des traitements par les anti-TNFα

Revue de Medecine Interne

Volumn 31, Issue 5, 2010, Pages 353-360

  Marie, I ^a   Guglielmino, E ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Adalimumab; Anti TNF ; Etanercept; Infliximab; Mortality; Opportunistic infections; Prophylaxis

Indexed keywords

ADALIMUMAB; COTRIMOXAZOLE; ETANERCEPT; FOSCARNET; GANCICLOVIR; INFLIXIMAB; ITRACONAZOLE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; HEPATITIS; HERPES VIRUS INFECTION; HISTOPLASMOSIS; HUMAN; LEISHMANIASIS; MORBIDITY; MORTALITY; MYCOBACTERIOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS; PNEUMOCYSTOSIS; SHORT SURVEY; STRONGYLOIDIASIS; TOXOPLASMOSIS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; OPPORTUNISTIC INFECTIONS; PARASITIC DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPONDYLARTHRITIS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 77952543936     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.04.010     Document Type: Short Survey

References (67)

1. Tubach F., Salmon-Céron D., Ravaud P., Mariette X. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF-alpha therapy. Joint Bone Spine 2005, 72:456-460. For the RATIO study group.
2. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-α antagonists. Arthritis Rheum 2007, 56:1125-1133.
3. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., Beenhouwer D.O. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
4. Wallis R.S., Broder M.S., Wong J., Hanson M.E., Beenhouwer D.O. Granulomatous infectious diseases associated with tumour necrosis factor antagonists: correction. Clin Infect Dis 2004, 39:2517-2518.
5. Larsen M.V., Sorensen I.J., Thomsen V.O., Ravn P. Re-activation of bovine tuberculosis in a patient, treated with infliximab. Eur Respir J 2008, 32:229-231.
6. Maimon N., Brunton J., Chan A.K., Marras T.K. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007, 62:739-740.
7. Eisendle K., Fritsch P. Fatal fulminant legionnaire's disease in a patient with severe erythrodermic psoriasis treated with infliximab after long-term steroid. Br J Dermatol 2005, 152:565-595.
8. Tubach F., Ravaud P., Salmon-Ceron D., Petitpain N., Brocq O., Grados F., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006, 43:e95-100.
9. Izbeki F., Nagy F., Szepes Z., Kiss I., Lonovics J., Molnar T. Severe Listeria meningoencephalitis in an infliximab-tretaed patient with Crohn's disease. Inflamm Bowel Dis 2008, 14:429-431.
10. Rachapalli S., O'Daunt S. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum 2005, 52:987.
11. Schett G., Herak P., Graninger W., Smolen J.S., Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005, 43:2537-2541.
12. Slifman N.R., Gershon S.K., Lee J.H., Edwards E.T., Braun M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor-α neutralizing agents. Arthritis Rheum 2003, 48:319-324.
13. Marie I., Heliot P., Roussel F., Herve F., Muir J.F., Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 2005, 44:1201-1202.
14. Martín-Aspas A., Guerrero-Sánchez F., García-Martos P., González-Moya E., Medina-Varo F., Girón González J.A. Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 2008, 57:167-169.
15. Salvana E.M., Cooper G.S., Salata R.A. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 2007, 55:484-487.
16. Stewart M.W., Alvarez S., Ginsburg W.W., Shetty R., McLain W.C., Sleater J.P. Visual recovery following Mycobacterium chelonae endophtalmitis. Ocul Immunol Inflamm 2006, 14:181-183.
17. van Ingen J., Boeree M., Janssen M., Ullmann E., de Lange W., de Haas P., et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving antitumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007, 3:414-419.
18. Marie I., Lahaxe L., Levesque H., Heliot P. Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 2008, 101:419-421.
19. Singh S.M., Rau N.V., Cohen L.B., Harris H. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. CMAJ 2004, 171:1063-1064.
20. Tsiodras S., Samonis G., Boumpas D.T., Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-194.
21. Itaba S., Iwasa T., Sadamoto Y., Nasu T., Misawa T., Inoue K., et al. Pneumocystis pneumonia during combing therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. Dig Dis Sci 2007, 52:1438-1441.
22. Statakos G., Kalomenidis I., Paps V., Malagari K., Kollintza A., Roussos C., et al. Cough and fever in a female with Crohn's disease receiving infliximab. Eur Respir J 2005, 26:354-357.
23. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
24. Harigai M., Koike R., Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl Med J 2007, 357:1874-1876.
25. Finn S., Bond J., McCarthy D., Sheahan K., Quinn C. Angio-invasive aspergillosis presenting as neutropenic colitis. Histopathology 2006, 49:440-441.
26. Slusher J.R., Maldonado M.E., Mousavi F., Lozada C.J. Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy. Rheumatology 2008, 47:739-740.
27. Warris A., Bjorneklett A., Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001, 344:1099-1100.
28. Belda A., Hinojosa J., Serra B., García L., Merino C., Belda A., et al. Candidiasis sistémica y tratamiento con infliximab. Gastroenterol Hepatol 2004, 27:365-367.
29. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A.G., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The research in active rheumatoid arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739.
30. Arend S.M., Kuijper E.J., Allaart C.F., Hissink-Muller W., van Dissel J.T. Cavitating pneumonia after infliximab and prednisone. Eur J Clin Microbiol Infect Dis 2004, 23:638-641.
31. Kozic H., Riggs K., Ringpfeil F., Lee J.B. Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis. J Am Acad Dermatol 2008, 58:S95-S96.
32. Munoz P., Giannella M., Valerio M., Soria T., Diaz F., Longo J.L., et al. Cryptococcal meningitis in a patient treated with infliximab. Diag Microbiol Infect Dis 2007, 57:443-446.
33. Shrestha R.K., Stoller J.K., Honari G., Procop G.W., Gordon S.M. Pneumonia due Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004, 49:606-608.
34. Galandiuk S., Davis B.R. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2008, 5:283-287.
35. Nakelchik M., Mangino J.E. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002, 112:78.
36. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-α antagonists: infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
37. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
38. Odessey E., Cohn A., Beaman K., Schechter L. Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect 2008, 9:91-98.
39. Singh P., Taylor S.F., Murali R., Gomes L.J., Kanthan G.L., Mallof A.J. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumor necrosis factor-α inhibitor. Clin Exp Ophtalmol 2007, 35:275-280.
40. Lowther A.L., Somani A.K., Camouse M., Florentino F.T., Somach S.C. Invasive Tripchophyton rubrum infection and long-term prednisone treatment. J Cutan Med Surg 2007, 11:84-88.
41. Gottlieb G.S., Lesser C.F., Holmes K.K., Wald A. Disseminated Sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-α antagonists. Clin Infect Dis 2003, 37:838-840.
42. Garcia-Vidal C., Rodríguez-Fernández S., Teijón S., Esteve M., Rodríguez-Carballeira M., Lacasa J.M., et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009, 28:331-337.
43. Leung V.S., Nguyen M.T., Bush T.M. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004, 99:2503-2504.
44. Colombel J.F., Loftus E.V., Tremaine W.J., Egan L.J., Harmsen S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
45. Tai Y.J., Kelly R. Pyoderma gangrenosum complicated by herpes simplex infection. Australas J Dermatol 2005, 46:161-164.
46. Sari I., Birlik M., Akar S., Gurel D., Onen F., Akkoc N. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008, 14:2912-2914.
47. Lavagna A., Bergallo M., Daperno M., Sostegni R., Costa C., Leto R., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13:896-902.
48. D'Ovidio V., Vernia P., Gentile G., Capobianchi A., Marcheggiano A., Viscido A., et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNF-α therapy. J Clin Virol 2008, 43:180-183.
49. Haerter G., Manfras B.J., de Jong-Hesse Y., Wilts H., Mertens T., Kern P., et al. Cytomegalovirus retinitis in a patient treated with antitumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004, 39:e88-94.
50. Balandraud N., Guis S., Meynard J.B., Auger I., Roudier J., Roudier C. Long-term treatment with methotrexate or tumor necrosis factor-α inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:762-767.
51. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007, 13:508-509.
52. Millionig G., Kern M., Ludwiczek O., Nachbaur K., Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 2006, 12:974-976.
53. Montiel P.M., Solis J.A., Chirinos J.A., a Casis B., Sánchez F., Rodríguez S. Hepatitis B reactivation during therapy with etanercept in an HBs-Ag-negative and anti-HBs-positive patient. Liver Int 2008, 28:718-720.
54. Raftery G., Griffiths B., Kay L., Kane D. Chronic viral hepatitis and TNF-α blockade. Rheumatology 2007, 46:1381.
55. Cansu D.U., Kalifoglu T., Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying drugs without antiviral prophylaxis. J Rheumatol 2008, 35:421-424.
56. Niewold T.B., Gibofsky A. Concomitant interferon-α therapy and tumor necrosis factor-α inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006, 54:2335-2337.
57. Peterson J.R., Hsu F.C., Simkin P.A., Wener M.K. Effect of tumor necrosis factor-α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62:1078-1082.
58. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo, Miossec P. Etanercept treatment for 3 months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007, 46:97-99.
59. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., Reveille J.D. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008, 67:710-712.
60. Filippi J., Roger P.M., Schneider S.M., Durant J., Breittmayer J.P., Benzaken S., et al. Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T cell loss related to apoptosis. Arch Intern Med 2006, 166:1783-1784.
61. Cohen C.D., Horster S., Sander C.A., Bogner J.R. Kaposi's sarcoma associated with tumour necrosis factor-α neutralizing therapy. Ann Rheum Dis 2003, 62:684.
62. Young J.D., McGwire B.S. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 2005, 353:1530-1531.
63. Bassetti M., Pizorni C., Gradoni L., del Bono V., Cutolo M., et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 2006, 45:1446-1448.
64. Tektonidou M.G., Skopouli F.N. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. Clin Rheumatol 2008, 27:541-542.
65. Boatright M.D., Wang B.W.E. Clinical infection with Strongyloides stercoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum 2005, 52:1336-1337.
66. Marie I. Infections au cours des polymyosites et des dermatomyosites. Presse Med 2009, 38:303-316.
67. Coyle C.M., Weiss L.M., Rhodes L.V., Cali A., Takvorian P.M., Brown D.F., et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004, 351:42-47.